Thulium Laser and Growth Factors for Androgenetic Alopecia
1 other identifier
interventional
30
1 country
1
Brief Summary
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2023
CompletedFirst Submitted
Initial submission to the registry
July 13, 2025
CompletedFirst Posted
Study publicly available on registry
July 23, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedJuly 23, 2025
July 1, 2025
1.8 years
July 13, 2025
July 21, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Subject Global Aesthetic Improvement Scale
scale from 0 (very much improved) to 4 (worse)
1 and 6 months post-treatment
Hair density
measurement of hair density before and after treatment
at baseline, and 1 and 6 months post-treatment
hair thickness
hair thickness before and after treatment
at baseline, and 1 and 6 months post-treatment
Secondary Outcomes (1)
pain intensity
Periprocedural
Study Arms (3)
Thulium laser + growth factor serum + LED
ACTIVE COMPARATORThulium laser + growth factor serum + LED
Thulium laser + growth factor serum
ACTIVE COMPARATORThulium laser + growth factor serum
Thulium laser
ACTIVE COMPARATORThulium laser
Interventions
3 sessions at intervals of 6 weeks
3 sessions at intervals of 6 weeks
Eligibility Criteria
You may qualify if:
- Men and women aged 18 and over
- Good general health, no relevant previous illnesses
- Presence of an AGA
- Cognitive ability and willingness to give consent (informed consent)
- Be willing and able to attend follow-up visits
You may not qualify if:
- Age \< 18 years
- Pregnant or breastfeeding women
- Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
- Significant scarring of the region to be treated
- Significant open wounds or lesions in the region to be treated
- Metallic implants in the head region
- Mental illnesses (psychoses, body perception disorders)
- Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
- Resurfacing (fractional, ablative, non-ablative) of the affected region \< 2 months before and during the study period
- Tendency to excessive scarring
- Lack of informed consent and/or data protection declarations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Medical Center Hamburg-Eppendorf
Hamburg, Hamburg, 20246, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr. med.
Study Record Dates
First Submitted
July 13, 2025
First Posted
July 23, 2025
Study Start
December 1, 2023
Primary Completion
September 1, 2025
Study Completion
October 1, 2025
Last Updated
July 23, 2025
Record last verified: 2025-07